ACADIA Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACAD)

$29.18 -0.79 (-2.64 %)
(As of 12/12/2017 04:00 PM ET)
Previous Close$29.97
Today's Range$28.95 - $30.75
52-Week Range$24.31 - $41.20
Volume1.57 million shs
Average Volume1.65 million shs
Market Capitalization$3.79 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.8

About ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals logoACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACAD
CUSIPN/A
Phone858-558-2871

Debt

Debt-to-Equity RatioN/A
Current Ratio11.12%
Quick Ratio10.97%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$17.33 million
Price / Sales209.14
Cash FlowN/A
Price / CashN/A
Book Value$4.28 per share
Price / Book6.82

Profitability

Trailing EPS($2.45)
Net Income$-271,390,000.00
Net Margins-320.71%
Return on Equity-67.68%
Return on Assets-61.88%

Miscellaneous

Employees370
Outstanding Shares124,210,000

ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.63) by $0.10. The biopharmaceutical company earned $35.58 million during the quarter, compared to analysts' expectations of $32.03 million. ACADIA Pharmaceuticals had a negative return on equity of 67.68% and a negative net margin of 320.71%. The company's revenue for the quarter was up 571.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.61) EPS. View ACADIA Pharmaceuticals' Earnings History.

When will ACADIA Pharmaceuticals make its next earnings announcement?

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for ACADIA Pharmaceuticals.

Where is ACADIA Pharmaceuticals' stock going? Where will ACADIA Pharmaceuticals' stock price be in 2017?

12 analysts have issued 1-year price objectives for ACADIA Pharmaceuticals' shares. Their forecasts range from $29.00 to $61.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $49.42 in the next twelve months. View Analyst Ratings for ACADIA Pharmaceuticals.

What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (11/15/2017)
  • 2. HC Wainwright analysts commented, "HARMONY Study Initiation: Killing Multiple" Birds With One Stone? Reit Buy and $60 PT Initiation of the Ph3 HARMONY study is one step forward with our bull thesis. With the initiation of HARMONY study in dementia-related psychosis (DRP) and discontinuation of SEREN study in AD agitation, we applaud what we view as a smart move by Acadia of pursuing a broader indication for pimavanserin, and more importantly, doing so with a solid clinical plan moving forward. At first glance, the seemingly bold move into DRP from ADP may appear over-ambitious (killing multiple" birds with one stone). However, we note that a psychosis focus/approach may prove to be a smart play from both the commercial point of view and also from the mechanistic perspective. The blessing from the FDA with a Breakthrough Designation further elevates our sanguine outlook for the program. We highlight the significant upside coming with the DRP expansion as the target market is potentially bigger than ADP alone (if we assume ADP comprises 70% of the DRP)." (10/5/2017)
  • 3. Needham & Company LLC analysts commented, "Acadia reported $11.9M in 4Q16 Nuplazid sales, above our $9.0M estimate. Mgmt noted steady growth in number of prescribers, repeat prescribers, and new patients. Company also announced plan to expand sales force by 20 reps to address long-term care opportunity. There are no immediate plans to provide 2017 sales guidance. We believe stock is attractive given Nuplazid launch trajectory and likelihood for label expansion in long-term. Stock likely to be driven by sales in 2017 and Phase 2/3 results in other indications in 2018/ 2019. Acadia may be an attractive M&A target. BUY." (3/1/2017)

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 8,697,325 shares, an increase of 32.0% from the October 31st total of 6,591,263 shares. Based on an average daily volume of 2,441,101 shares, the days-to-cover ratio is presently 3.6 days. Approximately 7.1% of the shares of the stock are short sold.

Who are some of ACADIA Pharmaceuticals' key competitors?

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the folowing people:

  • Stephen R. Biggar M.D. Ph.D., Chairman of the Board (Age 46)
  • Stephen R. Davis, President, Chief Executive Officer, Director (Age 56)
  • Todd S. Young, Executive Vice President, Chief Financial Officer (Age 45)
  • Glenn F. Baity, Executive Vice President, General Counsel, Secretary (Age 47)
  • Srdjan Stankovic M.D., Executive Vice President, Head - Research and Development (Age 60)
  • Michael J. Yang, Executive Vice President, Chief Commercial Officer (Age 55)
  • Edmund P. Harrigan M.D., Director (Age 64)
  • Julian C. Baker, Independent Director (Age 50)
  • Laura A. Brege, Independent Director (Age 59)
  • James M. Daly, Independent Director (Age 55)

Who owns ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (22.10%), Janus Henderson Group PLC (4.80%), JPMorgan Chase & Co. (1.51%), Pictet Asset Management Ltd. (1.09%), First Trust Advisors LP (0.99%) and Ameriprise Financial Inc. (0.73%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Edmund Harrigan, Glenn Baity, Leslie L Iversen, LP 14159 and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

Who sold ACADIA Pharmaceuticals stock? Who is selling ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Frontier Capital Management Co. LLC, First Trust Advisors LP, Ameriprise Financial Inc., Alyeska Investment Group L.P., Tocqueville Asset Management L.P., Candriam Luxembourg S.C.A. and TD Asset Management Inc.. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Glenn Baity and Terrence O Moore. View Insider Buying and Selling for ACADIA Pharmaceuticals.

Who bought ACADIA Pharmaceuticals stock? Who is buying ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Pictet Asset Management Ltd., Gilder Gagnon Howe & Co. LLC, Dimensional Fund Advisors LP, Sivik Global Healthcare LLC, Schwab Charles Investment Management Inc., Van ECK Associates Corp and Bank of New York Mellon Corp. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Edmund Harrigan and LP 14159. View Insider Buying and Selling for ACADIA Pharmaceuticals.

How do I buy ACADIA Pharmaceuticals stock?

Shares of ACADIA Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACADIA Pharmaceuticals stock can currently be purchased for approximately $29.18.

How big of a company is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has a market capitalization of $3.79 billion and generates $17.33 million in revenue each year. The biopharmaceutical company earns $-271,390,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. ACADIA Pharmaceuticals employs 370 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]


MarketBeat Community Rating for ACADIA Pharmaceuticals (ACAD)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  473 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  678
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ACADIA Pharmaceuticals (NASDAQ:ACAD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.712.712.71
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $47.07$47.07$44.00$43.00
Price Target Upside: 58.86% upside58.86% upside32.49% upside54.40% upside

ACADIA Pharmaceuticals (NASDAQ:ACAD) Consensus Price Target History

Price Target History for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ:ACAD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017HC WainwrightReiterated RatingBuy$60.00N/AView Rating Details
11/7/2017CowenReiterated RatingBuy$46.00N/AView Rating Details
10/12/2017Jefferies GroupReiterated RatingBuy$47.00N/AView Rating Details
10/9/2017Leerink SwannReiterated RatingMarket PerformN/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingNeutral$45.00N/AView Rating Details
10/5/2017J P Morgan Chase & CoSet Price TargetBuy$50.00N/AView Rating Details
10/5/2017Piper Jaffray CompaniesReiterated RatingBuy$54.00 -> $61.00N/AView Rating Details
10/5/2017Bank of AmericaBoost Price TargetBuy -> Positive$40.00 -> $46.00N/AView Rating Details
10/5/2017JMP SecuritiesBoost Price TargetOutperform$47.00 -> $50.00N/AView Rating Details
10/2/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$48.00 -> $50.00LowView Rating Details
9/17/2017Needham & Company LLCReiterated RatingBuy$49.00LowView Rating Details
5/22/2017Rodman & RenshawReiterated RatingBuy$60.00LowView Rating Details
10/19/2016Roth CapitalReiterated RatingNeutral$25.00N/AView Rating Details
8/5/2016AegisDowngradeBuy -> Hold$54.00 -> $41.00N/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earnings History and Estimates Chart

Earnings by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ ACAD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.58)N/AView Earnings Details
11/7/2017Q3 2017($0.63)($0.53)$32.03 million$35.58 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.72)($0.55)$20.02 million$30.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.73)($0.72)$15.17 million$15.30 millionViewListenView Earnings Details
2/28/2017Q416($0.65)($0.65)$9.05 million$12.00 millionViewListenView Earnings Details
11/7/2016Q316($0.56)($0.61)$2.90 million$5.30 millionViewListenView Earnings Details
8/4/2016Q216($0.49)($0.63)$0.71 million$0.97 millionViewListenView Earnings Details
5/5/2016Q116($0.42)($0.45)$0.22 millionViewListenView Earnings Details
2/29/2016Q415($0.38)($0.45)$0.02 millionViewListenView Earnings Details
11/5/2015Q315($0.40)($0.39)$0.05 million$0.04 millionViewListenView Earnings Details
8/6/2015Q215($0.33)($0.39)$0.06 millionViewListenView Earnings Details
5/7/2015Q115($0.25)($0.40)$0.09 millionViewListenView Earnings Details
2/26/2015Q414($0.26)($0.28)$0.08 million$0.05 millionViewListenView Earnings Details
11/10/2014Q3($0.12)($0.25)$0.02 millionViewListenView Earnings Details
8/5/2014Q2($0.17)($0.22)$0.10 million$0.03 millionViewListenView Earnings Details
5/6/2014Q1($0.13)($0.19)$0.50 million$0.03 millionViewListenView Earnings Details
2/27/2014Q4($0.14)($0.13)ViewListenView Earnings Details
8/6/2013Q2 2013($0.09)($0.11)$0.45 million$451.00 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.08)($0.08)$0.45 million$0.42 millionViewListenView Earnings Details
11/5/2012Q312($0.09)($0.04)$1.90 million$3.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earnings Estimates

2017 EPS Consensus Estimate: ($2.26)
2018 EPS Consensus Estimate: ($1.91)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.75)($0.53)($0.64)
Q2 20172($0.71)($0.48)($0.60)
Q3 20172($0.64)($0.44)($0.54)
Q4 20172($0.57)($0.39)($0.48)
Q1 20181($0.55)($0.55)($0.55)
Q2 20181($0.50)($0.50)($0.50)
Q3 20181($0.45)($0.45)($0.45)
Q4 20181($0.41)($0.41)($0.41)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ACADIA Pharmaceuticals (NASDAQ:ACAD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ACADIA Pharmaceuticals (NASDAQ ACAD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 22.25%
Institutional Ownership Percentage: 94.03%
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

ACADIA Pharmaceuticals (NASDAQ ACAD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/5/2017Glenn BaityEVPSell37,500$40.91$1,534,125.00View SEC Filing  
8/30/2017Glenn BaityEVPSell26,507$34.87$924,299.09View SEC Filing  
8/9/2017Glenn BaityEVPSell14,322$34.88$499,551.36View SEC Filing  
7/20/2017Glenn BaityEVPSell38,097$30.00$1,142,910.00View SEC Filing  
6/22/2017Glenn BaityEVPSell1,903$30.00$57,090.00View SEC Filing  
2/16/2017Terrence O. MooreEVPSell157,540$39.77$6,265,365.80View SEC Filing  
12/27/2016Glenn BaityEVPSell9,800$30.46$298,508.00View SEC Filing  
12/20/2016Glenn BaityEVPSell10,000$30.00$300,000.00View SEC Filing  
8/16/2016Edmund HarriganDirectorBuy1,000$32.97$32,970.00View SEC Filing  
8/10/2016Bros. Advisors Lp BakerDirectorBuy1,303,030$33.00$42,999,990.00View SEC Filing  
7/12/2016Glenn BaityEVPSell16,000$35.00$560,000.00View SEC Filing  
7/11/2016Glenn BaityEVPSell4,057$35.00$141,995.00View SEC Filing  
4/18/2016Leslie L IversenDirectorSell33,697$33.53$1,129,860.41View SEC Filing  
4/1/2016Bros. Advisors Lp BakerDirectorBuy1,449,090$27.08$39,241,357.20View SEC Filing  
1/7/2016L.P. 14159DirectorBuy2,586,206$29.00$74,999,974.00View SEC Filing  
11/11/2015Leslie L. IversenDirectorSell30,000$36.01$1,080,300.00View SEC Filing  
1/15/2015Michael T BorerDirectorSell27,973$33.02$923,668.46View SEC Filing  
1/14/2015Uli HacksellCEOSell30,000$33.98$1,019,400.00View SEC Filing  
12/15/2014Mary Ann GrayDirectorSell12,250$31.74$388,815.00View SEC Filing  
12/15/2014Uli HacksellCEOSell30,000$31.00$930,000.00View SEC Filing  
11/26/2014Michael T BorerDirectorSell15,000$30.05$450,750.00View SEC Filing  
11/26/2014Roger MillsCMOSell25,000$30.09$752,250.00View SEC Filing  
11/24/2014Uli HacksellCEOSell30,000$29.28$878,400.00View SEC Filing  
11/21/2014William Mcdowall WellsDirectorSell5,810$29.00$168,490.00View SEC Filing  
10/8/2014Uli HacksellCEOSell30,000$24.15$724,500.00View SEC Filing  
9/15/2014Laura BregeDirectorSell10,000$28.07$280,700.00View SEC Filing  
9/12/2014William Mcdowall WellsDirectorSell9,190$29.15$267,888.50View SEC Filing  
9/10/2014Uli HacksellCEOSell30,000$27.36$820,800.00View SEC Filing  
8/15/2014Uli HacksellCEOSell15,000$22.89$343,350.00View SEC Filing  
7/14/2014Uli HacksellCEOSell20,000$22.22$444,400.00View SEC Filing  
6/16/2014Uli HacksellCEOSell20,000$23.10$462,000.00View SEC Filing  
6/9/2014William Mcdowall WellsDirectorSell15,000$23.03$345,450.00View SEC Filing  
5/1/2014Torsten RasmussenDirectorSell32,857$20.03$658,125.71View SEC Filing  
4/15/2014Uli HacksellCEOSell25,000$17.75$443,750.00View SEC Filing  
4/4/2014Thomas AasenCFOSell15,000$22.48$337,200.00View SEC Filing  
4/4/2014Torsten RasmussenDirectorSell30,000$21.98$659,400.00View SEC Filing  
3/5/2014Bros. Advisors Lp BakerDirectorBuy526,316$28.50$15,000,006.00View SEC Filing  
2/26/2014Glenn BaityVPSell42,000$30.28$1,271,760.00View SEC Filing  
11/1/2013Torsten RasmussenDirectorSell37,692$23.00$866,916.00View SEC Filing  
11/1/2013Uli HacksellCEOSell15,000$23.24$348,600.00View SEC Filing  
10/10/2013Laura BregeDirectorSell10,000$21.63$216,300.00View SEC Filing  
10/1/2013Thomas H AasenCFOSell30,000$27.87$836,100.00View SEC Filing  
9/20/2013Roger MillsCMOSell35,965$25.01$899,484.65View SEC Filing  
9/12/2013Lester Ph KaplanDirectorSell66,356$22.90$1,519,552.40View SEC Filing  
9/10/2013Laura BregeDirectorSell46,153$22.80$1,052,288.40View SEC Filing  
9/3/2013Torsten RasmussenDirectorSell40,000$20.28$811,200.00View SEC Filing  
8/26/2013Mary Ann GrayDirectorSell15,000$20.68$310,200.00View SEC Filing  
8/13/2013Thomas AasenCFOSell60,000$20.15$1,209,000.00View SEC Filing  
8/13/2013Uli HacksellCEOSell52,771$20.14$1,062,807.94View SEC Filing  
6/5/2013Felix BakerDirectorBuy2,340,314$14.34$33,560,102.76View SEC Filing  
5/15/2013Felix BakerDirectorBuy1,993,000$12.50$24,912,500.00View SEC Filing  
4/12/2013Glenn BaityVPSell60,000$12.42$745,200.00View SEC Filing  
4/11/2013Thomas H AasenCFOSell40,000$11.06$442,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ACADIA Pharmaceuticals (NASDAQ ACAD) News Headlines

Source:
DateHeadline
Cramer Remix: Acadia is the most volatile stock I’ve ever covered — and it’s worth speculating onCramer Remix: Acadia is the most volatile stock I’ve ever covered — and it’s worth speculating on
finance.yahoo.com - December 12 at 3:23 PM
Albany Molecular Research (AMRI) vs. ACADIA Pharmaceuticals (ACAD) Head to Head ReviewAlbany Molecular Research (AMRI) vs. ACADIA Pharmaceuticals (ACAD) Head to Head Review
www.americanbankingnews.com - December 9 at 11:28 AM
ACADIA Pharmaceuticals Inc. (ACAD) Receives Average Rating of "Buy" from BrokeragesACADIA Pharmaceuticals Inc. (ACAD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 8 at 3:52 PM
Today’s Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Moleculin BiotechToday’s Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Moleculin Biotech
finance.yahoo.com - December 6 at 8:13 AM
Can Acadia Pharmaceuticals Be A Prudent Bet For Long-Term Investors? - Seeking AlphaCan Acadia Pharmaceuticals Be A Prudent Bet For Long-Term Investors? - Seeking Alpha
seekingalpha.com - December 5 at 7:49 AM
Heres How Acadia Pharmaceuticals Crushed It in 2017 - Motley FoolHere's How Acadia Pharmaceuticals Crushed It in 2017 - Motley Fool
www.fool.com - December 4 at 3:23 PM
ACADIA Pharmaceuticals Inc. (ACAD) Expected to Announce Quarterly Sales of $45.04 MillionACADIA Pharmaceuticals Inc. (ACAD) Expected to Announce Quarterly Sales of $45.04 Million
www.americanbankingnews.com - December 4 at 12:52 PM
Here's How Acadia Pharmaceuticals Crushed It in 2017Here's How Acadia Pharmaceuticals Crushed It in 2017
finance.yahoo.com - December 4 at 7:52 AM
 Brokerages Anticipate ACADIA Pharmaceuticals Inc. (ACAD) to Post -$0.59 EPS Brokerages Anticipate ACADIA Pharmaceuticals Inc. (ACAD) to Post -$0.59 EPS
www.americanbankingnews.com - December 2 at 7:24 AM
Commercialisation Of Biologics: Benchmarking Leading PlayersCommercialisation Of Biologics: Benchmarking Leading Players
www.bizjournals.com - November 29 at 3:22 PM
ACADIA Pharmaceuticals Inc. (ACAD) Short Interest UpdateACADIA Pharmaceuticals Inc. (ACAD) Short Interest Update
www.americanbankingnews.com - November 27 at 11:32 PM
Acadia Pharmaceuticals: The Harmony Trial And Buyout Potential ... - Seeking AlphaAcadia Pharmaceuticals: The Harmony Trial And Buyout Potential ... - Seeking Alpha
seekingalpha.com - November 27 at 3:18 PM
Spectrum Doubles in 3 Months: What's Driving the Rally?Spectrum Doubles in 3 Months: What's Driving the Rally?
finance.yahoo.com - November 27 at 3:18 PM
ACADIA Pharmaceuticals Inc. (ACAD) Rating Lowered to Sell at ValuEngineACADIA Pharmaceuticals Inc. (ACAD) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - November 26 at 2:16 PM
ACAD January 2018 Options Begin TradingACAD January 2018 Options Begin Trading
www.nasdaq.com - November 22 at 9:03 PM
ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017
finance.yahoo.com - November 21 at 3:59 PM
Opus Point Partners Management, LLC Buys Bioverativ Inc, ACADIA Pharmaceuticals Inc, United ... - NasdaqOpus Point Partners Management, LLC Buys Bioverativ Inc, ACADIA Pharmaceuticals Inc, United ... - Nasdaq
www.nasdaq.com - November 18 at 8:23 AM
ACADIA Pharmaceuticals Sees Unusually Large Options Volume (ACAD)ACADIA Pharmaceuticals Sees Unusually Large Options Volume (ACAD)
www.americanbankingnews.com - November 17 at 1:26 AM
Billionaire Israel “Izzy” Englander Bets on Troubled Pharma Giants Teva and Valeant, Nixes AcadiaBillionaire Israel “Izzy” Englander Bets on Troubled Pharma Giants Teva and Valeant, Nixes Acadia
finance.yahoo.com - November 16 at 3:39 PM
ACADIA Pharmaceuticals Inc. (ACAD) Upgraded at Zacks Investment ResearchACADIA Pharmaceuticals Inc. (ACAD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - November 15 at 9:00 PM
ACADIA Pharmaceuticals Has This Top Analyst Even More Positive on PDP Drug Nuplazid’s OpportunityACADIA Pharmaceuticals Has This Top Analyst Even More Positive on PDP Drug Nuplazid’s Opportunity
finance.yahoo.com - November 13 at 5:23 PM
ACADIA Pharmaceuticals Inc. (ACAD) Given Average Recommendation of "Buy" by AnalystsACADIA Pharmaceuticals Inc. (ACAD) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 13 at 3:03 PM
Better Buy: Acadia Pharmaceuticals vs. Biogen - Motley FoolBetter Buy: Acadia Pharmaceuticals vs. Biogen - Motley Fool
www.fool.com - November 12 at 8:29 PM
ACADIA Pharmaceuticals (ACAD) CEO Steve Davis on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaACADIA Pharmaceuticals' (ACAD) CEO Steve Davis on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 12 at 3:28 PM
ACADIA Pharmaceuticals Inc. (ACAD) Forecasted to Post FY2017 Earnings of ($2.38) Per ShareACADIA Pharmaceuticals Inc. (ACAD) Forecasted to Post FY2017 Earnings of ($2.38) Per Share
www.americanbankingnews.com - November 10 at 8:38 AM
Why Biotech Acadia May Be OversoldWhy Biotech Acadia May Be Oversold
finance.yahoo.com - November 9 at 4:21 PM
HC Wainwright Reaffirms "Buy" Rating for ACADIA Pharmaceuticals Inc. (ACAD)HC Wainwright Reaffirms "Buy" Rating for ACADIA Pharmaceuticals Inc. (ACAD)
www.americanbankingnews.com - November 8 at 11:10 PM
Acadia Pharmaceuticals is Now Oversold (ACAD)Acadia Pharmaceuticals is Now Oversold (ACAD)
www.nasdaq.com - November 8 at 5:19 PM
Edited Transcript of ACAD earnings conference call or presentation 7-Nov-17 10:00pm GMTEdited Transcript of ACAD earnings conference call or presentation 7-Nov-17 10:00pm GMT
finance.yahoo.com - November 8 at 5:19 PM
Leerink Swann Weighs in on ACADIA Pharmaceuticals Inc.s Q1 2018 Earnings (ACAD)Leerink Swann Weighs in on ACADIA Pharmaceuticals Inc.'s Q1 2018 Earnings (ACAD)
www.americanbankingnews.com - November 8 at 4:40 PM
H.C. Wainwright: Acadia Is More Than A One-Trick PonyH.C. Wainwright: Acadia Is More Than A One-Trick Pony
feeds.benzinga.com - November 8 at 12:43 PM
Earnings Reaction History: ACADIA Pharmaceuticals Inc, 62.5% Follow-Through Indicator, 7.0% SensitiveEarnings Reaction History: ACADIA Pharmaceuticals Inc, 62.5% Follow-Through Indicator, 7.0% Sensitive
www.nasdaq.com - November 7 at 10:02 PM
Is It Time To Buy ACADIA Pharmaceuticals Inc (ACAD)?Is It Time To Buy ACADIA Pharmaceuticals Inc (ACAD)?
finance.yahoo.com - November 7 at 10:02 PM
ACADIA Pharmaceuticals Inc. (ACAD) Announces Quarterly  Earnings ResultsACADIA Pharmaceuticals Inc. (ACAD) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 7 at 5:27 PM
ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results - Business Wire (press release)ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - November 7 at 4:54 PM
ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial ResultsACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 4:54 PM
Acadia reports 3Q lossAcadia reports 3Q loss
finance.yahoo.com - November 7 at 4:54 PM
ACADIA Pharmaceuticals Inc. (ACAD) 3Q:17 Net Sales Grew to $35.6 MillionACADIA Pharmaceuticals Inc. (ACAD) 3Q:17 Net Sales Grew to $35.6 Million
finance.yahoo.com - November 7 at 4:54 PM
Tesaro, Acadia, Nektar Beat Third-Quarter ExpectationsTesaro, Acadia, Nektar Beat Third-Quarter Expectations
finance.yahoo.com - November 7 at 4:54 PM
Acadia Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for ACADAcadia Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for ACAD
www.nasdaq.com - November 6 at 9:11 PM
ETFs with exposure to ACADIA Pharmaceuticals, Inc. : November 6, 2017ETFs with exposure to ACADIA Pharmaceuticals, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 4:10 PM
Acadia Pharma (ACAD) Phase II Study of Pimavanserin in Alzheimers Met Primary EndpointAcadia Pharma (ACAD) Phase II Study of Pimavanserin in Alzheimer's Met Primary Endpoint
www.streetinsider.com - November 4 at 4:56 PM
ACADIA Pharmaceuticals Inc. (ACAD) Announces Presentation of Data Showing Greater Benefit in Patients with Severe PsychosisACADIA Pharmaceuticals Inc. (ACAD) Announces Presentation of Data Showing Greater Benefit in Patients with Severe Psychosis
finance.yahoo.com - November 4 at 4:56 PM
ACADIA Pharmaceuticals Presents Data from the Phase II Study of Pimavanserin in Alzheimers Disease Psychosis at ... - Business Wire (press release)ACADIA Pharmaceuticals Presents Data from the Phase II Study of Pimavanserin in Alzheimer's Disease Psychosis at ... - Business Wire (press release)
www.businesswire.com - November 3 at 3:15 PM
Acadia Pharmaceuticals Scores Relative Strength Rating Upgrade; Hits Key ThresholdAcadia Pharmaceuticals Scores Relative Strength Rating Upgrade; Hits Key Threshold
finance.yahoo.com - November 3 at 3:15 PM
ACADIA Pharmaceuticals Presents Data from the Phase II Study of Pimavanserin in Alzheimer’s Disease Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2017 MeetingACADIA Pharmaceuticals Presents Data from the Phase II Study of Pimavanserin in Alzheimer’s Disease Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2017 Meeting
finance.yahoo.com - November 3 at 3:15 PM
ACADIA Pharmaceuticals Inc. (ACAD) Announces Presentation of Data Showing Greater Benefit in Patients with More Severe PsychosisACADIA Pharmaceuticals Inc. (ACAD) Announces Presentation of Data Showing Greater Benefit in Patients with More Severe Psychosis
finance.yahoo.com - November 3 at 3:15 PM
Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3? - NasdaqIs ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3? - Nasdaq
www.nasdaq.com - October 31 at 4:30 PM
ACADIA Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017 - Business Wire (press release)ACADIA Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017 - Business Wire (press release)
www.businesswire.com - October 31 at 4:30 PM
Consolidated Research: 2018 Summary Expectations for Columbia Property Trust, Dr Pepper Snapple, Immune Pharmaceuticals, Air Products and Chemicals, Box, and ACADIA Pharma – Fundamental Analysis, Key Performance IndicationsConsolidated Research: 2018 Summary Expectations for Columbia Property Trust, Dr Pepper Snapple, Immune Pharmaceuticals, Air Products and Chemicals, Box, and ACADIA Pharma – Fundamental Analysis, Key Performance Indications
finance.yahoo.com - October 31 at 4:30 PM

SEC Filings

ACADIA Pharmaceuticals (NASDAQ:ACAD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ACADIA Pharmaceuticals (NASDAQ:ACAD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ACADIA Pharmaceuticals (NASDAQ ACAD) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.